A5037555787- Bone health and osteoporosis research
- Bone health and treatments
- Bone Metabolism and Diseases
- Hip and Femur Fractures
- Bone and Joint Diseases
- Vitamin D Research Studies
- Parathyroid Disorders and Treatments
- Bone fractures and treatments
- Meta-analysis and systematic reviews
- Body Composition Measurement Techniques
- Hip disorders and treatments
- Nutrition and Health in Aging
- Pelvic and Acetabular Injuries
- Estrogen and related hormone effects
- Clinical practice guidelines implementation
- Health Systems, Economic Evaluations, Quality of Life
- Folate and B Vitamins Research
- Alkaline Phosphatase Research Studies
- Spine and Intervertebral Disc Pathology
- Medical and Biological Sciences
- Management of metastatic bone disease
- Medical Imaging and Analysis
- Cardiac, Anesthesia and Surgical Outcomes
- Medical Imaging Techniques and Applications
- Orthopaedic implants and arthroplasty
New Mexico Clinical Research & Osteoporosis Center
2016-2025
University of New Mexico
2016-2025
University of Sheffield
2022
Bone Health and Osteoporosis Foundation
2022
International Society for Clinical Densitometry
2022
Versus Arthritis
2022
New Mexico Department of Health
2020-2021
Cedars-Sinai Medical Center
2021
Amsterdam UMC Location VUmc
2021
China Medical University
2019
The Clinician's Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee the National Foundation (NOF) in collaboration with a multispecialty council medical experts field bone health convened NOF. Readers are urged consult current prescribing information on any drug, device, or procedure discussed this publication.
Romosozumab, a monoclonal antibody that binds sclerostin, increases bone formation and decreases resorption.We enrolled 7180 postmenopausal women who had T score of -2.5 to -3.5 at the total hip or femoral neck. Patients were randomly assigned receive subcutaneous injections romosozumab (at dose 210 mg) placebo monthly for 12 months; thereafter, patients in each group received denosumab months, 60 mg, administered subcutaneously every 6 months. The coprimary end points cumulative incidences...
Receptor activator of nuclear factor-kappaB ligand (RANKL) is essential for osteoclast differentiation, activation, and survival. The fully human monoclonal antibody denosumab (formerly known as AMG 162) binds RANKL with high affinity specificity inhibits action.The efficacy safety subcutaneously administered were evaluated over a period 12 months in 412 postmenopausal women low bone mineral density (T score -1.8 to -4.0 at the lumbar spine or -3.5 proximal femur). Subjects randomly assigned...
Osteoporosis is the most common metabolic bone disease in USA and world. It a subclinical condition until complicated by fracture(s). These fractures place an enormous medical personal burden on individuals who suffer from them take significant economic toll. Any new fracture adult aged 50 years or older signifies imminent elevated risk for subsequent fractures, particularly year following initial fracture. What patient perceives as unfortunate accident may be seen sentinel event indicative...
Abstract Background: At the Third International Workshop on Asymptomatic Primary Hyperparathyroidism (PHPT) in May 2008, recent data disease were reviewed. We present results of a literature review issues arising from clinical presentation and natural history PHPT. Methods: Questions developed by Task Force A comprehensive search for relevant studies was reviewed, questions addressed Consensus Panel. Conclusions: 1) Data extent nature cardiovascular involvement those with mild are too...
This report summarizes data on traditional and nontraditional manifestations of primary hyperparathyroidism (PHPT) that have been published since the last International Workshop PHPT.This subgroup was constituted by Steering Committee to address key questions related presentation PHPT. Consensus established at a closed meeting Expert Panel followed.Data from 5-year period between 2008 2013 were presented discussed determine whether they support changes in recommendations for surgery or...
Denosumab is a monoclonal antibody to RANKL. In this randomized, placebo-controlled study of 412 postmenopausal women with low BMD, subcutaneous denosumab given every 3 or 6 mo was well tolerated, increased and decreased bone resorption markers for up 24 mo. Continued warranted in the treatment BMD women.Denosumab fully human that inhibits RANKL, key mediator osteoclastogenesis remodeling. This prespecified exploratory analysis evaluated efficacy safety through BMD.Four hundred twelve lumbar...
The FREEDOM study and its Extension provide long-term information about the effects of denosumab for treatment postmenopausal osteoporosis. Treatment up to 8 years was associated with persistent reduction bone turnover, continued increases in mineral density, low fracture incidence, a favorable benefit/risk profile.This aims report results through year 5 study, representing women osteoporosis.Women who completed 3-year were eligible enter 7-year open-label which all participants are...
Globally, one in five men aged >50 years is predicted to experience an osteoporotic fracture. Because of the treatment gap osteoporosis and paucity bone-forming agents for men, new treatments are needed. To evaluate safety efficacy romosozumab with osteoporosis. Phase III randomized BRIDGE study (placebo-controlled double-blind evaluating treating osteoporosis; ClinicalTrials.gov identifier, NCT02186171) 12 months. Thirty-one centers Europe, Latin America, Japan, North America. Men 55 90 a...
Stopping denosumab after 8 years of continued treatment was associated with bone loss during a 1-year observation study in patients who were not prescribed osteoporosis treatment. Bone attenuated began another therapy. Treatment to prevent upon stopping should be considered.This aimed understand management strategies observational follow-up up phase 2 study.During the year, received at discretion their physician and returned clinic for BMD assessment completion an questionnaire. Incidence...